HopeStage
Back to all studies
RecruitingISRCTN59554792

Xanomeline-trospium versus standard antipsychotics for cognition in early psychosis

About this title

The efficacy of xanomeline-trospium in treating cognitive impairment in psychosis: a randomised, double-blind active-controlled clinical trial

Read the official source — ISRCTN59554792
Research studyAges 18–55United KingdomSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 55 years.

Listed locations
United Kingdom

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
University of Oxford
Sponsor type
University
Study type
Other
Intervention type
Other / unclear
Locations
United Kingdom
Age range
From 18 Years to 55 Years
Official registry ID
ISRCTN59554792
Official title
Show the full official title

The efficacy of xanomeline-trospium in treating cognitive impairment in patients with a psychotic disorder

Recruitment & locations

Currently recruiting

United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Oxford, a university.

Who can participate?

Listed age limits: 18 years to 55 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies